Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR T cells) has shown excellent antitumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma (NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) by regulatory agencies in the United States, Europe, Canada, Japan, and Australia. This approval has transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4-6].

Source: Biology of Blood and Marrow Transplantation - October 8, 2019 Category: Hematology Authors: Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro, Evandro D. Bezerra, Vicky Wu, Jenna Voutsinas, Bronwen E. Shaw, Kathryn Flynn, Stephany J. Lee, Cameron J. Turtle, David G. Maloney, Jesse R. Fann, Merav Bar Source Type: research